Triglycerides contribute to the increased cardiovascular mortality in people with diabetes. Long-chain fatty acids are released from triglycerides in lesions of atherosclerosis, and are esterified to CoA in order to be utilized by vascular cells through a reaction that is catalyzed by long-chain acyI-CoA synthetases (ACS1-5). Oleic acid (OA), the most common fatty acid in triglycerides, has important pro-atherosclerotic effects in vascular cells. Four questions will be addressed: 1. Which ACS isoforms are expressed in primary smooth muscle cells (SMCs) and macrophages, and are they regulated by glucose and lipids? We hypothesize that primary SMCs and macrophages express several ACS isoforms, and that their expression is differentially regulated by glucose and lipids in vitro and in vivo. For the in vivo studies, we have developed a new transgenic mouse model of diabetes-accelerated atherosclerosis. 2. Is ACS2 necessary for OA incorporation into phosphatidylcholine and generation of OA-enriched 1,2-diacylglycerol following growth factor stimulation in SMCs? OA enhances the mitogenic effects of growth factors in SMCs by generation of OA-enriched 1,2-diacylglycerol (1,2-DAG) following growth factor-stimulation of phospholipase D. We hypothesize that ACS2 mediates OA-incorporation into phosphatidylcholine and generation of OA-enriched 1,2-DAG following growth factor stimulation. We propose to inhibit ACS2 by using ACS inhibitors and RNAi. 3. Is ACS2 necessary for the ability of OA to enhance growth factor-induced proliferation in SMCs? We hypothesize that ACS2 is necessary for the ability of OA to enhance growth factor-induced proliferation in SMCs. Inhibitors of ACS isoforms and RNAi will be used to inhibit OA-mediated potentiation of mitogenic effects of growth factors. 4. Which specific ACS isoform(s) is necessary for OA-induced macrophage death and inhibition of cholesterol efflux? OA induces macrophage death and inhibits cholesterol efflux. We hypothesize that a specific ACS isoform is necessary for these events. ACS inhibitors and RNAi will be used to determine the ACS isoform that mediates OA-induced effects on macrophage death, cholesterol efflux and lipid metabolism. The ACS isoforms in vascular cells have not been studied to date. We expect to identify ACS isoforms required for important biological effects of OA in primary smooth muscle and macrophages. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL076719-02
Application #
6869514
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Applebaum-Bowden, Deborah
Project Start
2004-04-01
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
2
Fiscal Year
2005
Total Cost
$379,000
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Zeng, Hongkui; Horie, Kyoji; Madisen, Linda et al. (2008) An inducible and reversible mouse genetic rescue system. PLoS Genet 4:e1000069
Johansson, Fredrik; Kramer, Farah; Barnhart, Shelley et al. (2008) Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci U S A 105:2082-7
Askari, Bardia; Kanter, Jenny E; Sherrid, Ashley M et al. (2007) Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 56:1143-52
Shen, Xia; Bornfeldt, Karin E (2007) Mouse models for studies of cardiovascular complications of type 1 diabetes. Ann N Y Acad Sci 1103:202-17
Kanter, Jenny E; Johansson, Fredrik; LeBoeuf, Renee C et al. (2007) Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques? Circ Res 100:769-81
MacDougall, Erin D; Kramer, Farah; Polinsky, Patti et al. (2006) Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice Am J Pathol 168:2064-73
Mashek, Douglas G; Bornfeldt, Karin E; Coleman, Rosalind A et al. (2004) Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family. J Lipid Res 45:1958-61
Renard, Catherine B; Kramer, Farah; Johansson, Fredrik et al. (2004) Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114:659-68
Lamharzi, Najib; Renard, Catherine B; Kramer, Farah et al. (2004) Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 53:3217-25